Epidarex and Sixth Element in $10m round for Adorx

The company intends to accelerate its research activities following the deal.

Epidarex, a founding investor in the company, has also introduced Pete Finan, formerly head of the Novartis Institutes of BioMedical Research UK site, as Adorx's CEO.

CRT Pioneer Fund was launched in 2012 and is backed by the European Investment Fund and the UK's Cancer Research Technology. The £70m vehicle is mandated to make investments in companies engaged in drug discovery and clinical developments in the field of cancer.

Company
Founded in 2017, Edinburgh-headquartered Adorx is a drug discovery company focused on identifying new modulators of the adenosine pathway for the treatment of cancer.

People
Epidarex Capital – Liz Roper (partner).
Sixth Element Capital – Ian Miscampbell (managing partner).
Adorx Therapeutics – Pete Finan (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture